This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neogen Comments On SenesTech

LANSING, Mich., July 24, 2014 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) advised market analysts today that future forecasts of its potential revenue from new rodenticide research are premature. In its regular quarterly conference call to investors and analysts on July 22, 2014, Neogen's CEO commented about several new developments when questioned by analysts regarding this research.

"It was my intent Tuesday at our conference call to answer questions about the potential of a new type of rodenticide, but certainly not to give any indication of size of that market," said James Herbert, Neogen's chief executive officer and chairman. "When asked about market studies, I declined any market projections since it is our intention to market this rodenticide in combination with our other current formulas. I also indicated that we hoped to submit application for approval to the U. S. Environmental Protection Agency sometime this summer, and though optimistic of eventual approval, could not forecast timing."

Neogen issued a press release on June 16, 2014, that it had licensed patents to a rodenticide aimed at controlling rodents through fertility control. The company indicated it was currently doing more beta site testing in field situations with natural rodent populations and was still awaiting those results before making any further investments.   

The company made these comments because of market reactions to published research on Wednesday that drove up both the price of the stock and volume. 

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division is a leader in the development of animal genomics, along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs